http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2856272-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4283 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2013-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a537d8c812a62ee64ebc53fa69b55716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bd32cd2449f8d92dd79ff76761dcc51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af226973a2cded1df8049b2cdb9fa5d4 |
| publicationDate | 2021-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2856272-T3 |
| titleOfInvention | Antigen-binding molecule to remove aggregated antigens |
| abstract | A method for producing an antibody that is capable of selectively removing disease-causing protein aggregates in preference to protein monomers from plasma, said method comprising the following steps: (a) selecting an antibody: (A) in which the ratio of the KD (dissociation constant) of the antibody to said protein aggregates under an intracellular pH of 5.8 and a calcium ion concentration of 3 μM at an extracellular pH of 7.4 and a calcium ion concentration of 1.2 mM is 2 or more: (B) wherein the FcRn receptor binding activity of a complex formed between said protein aggregates and the antibody is greater than the FcRn receptor binding activity of a complex formed between the non-protein aggregate and antibody; and (C) wherein the ratio of the plasma elimination of said added protein in the absence of said antibody to the plasma elimination of said added protein in the presence of said antibody is 1.5 or more times greater than the same elimination ratio. plasma for said non-aggregated protein; (b) culturing a host cell comprising a vector carrying a gene encoding the antibody selected in step (a); and (c) isolating the antibody from the culture obtained in step (b). |
| priorityDate | 2012-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1076.